This study aimed to reveal an alternative macrophage-mediated immunotherapy that simultaneously engaged FcγRI/CD64 receptors and prostate-specific membrane antigen present on the surface of host macrophages and prostate cancer cells, respectively. The gene discussed is FOLH1; the disease is prostate carcinoma.